%0 Journal Article
%A Galldiks, Norbert
%A Abdulla, Diana SY
%A Scheffler, Matthias
%A Wolpert, Fabian
%A Werner, Jan-Michael
%A Huellner, Martin W
%A Stoffels, Gabriele
%A Schweinsberg, Viola
%A Schlaak, Max
%A Kreuzberg, Nicole
%A Landsberg, Jennifer
%A Lohmann, Philipp
%A Ceccon, Garry
%A Baues, Christian
%A Trommer, Maike
%A Celik, Eren
%A Ruge, Maximilian I
%A Kocher, Martin
%A Marnitz, Simone
%A Fink, Gereon R
%A Tonn, Joerg-Christian
%A Weller, Michael
%A Langen, Karl-Josef
%A Wolf, Jürgen
%A Mauch, Cornelia
%T Treatment Monitoring of Immunotherapy and Targeted Therapy using 18 F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences
%J Journal of nuclear medicine
%V 62
%N 4
%@ 2159-662X
%C New York, NY
%I Soc.
%M FZJ-2021-00862
%P 464-470
%D 2021
%X We investigated the value of O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) PET for treatment monitoring of immune checkpoint inhibition (ICI) or targeted therapy (TT) alone or in combination with radiotherapy in patients with brain metastasis (BM) since contrast-enhanced MRI often remains inconclusive. Methods: We retrospectively identified 40 patients with 107 BMs secondary to melanoma (n = 29 with 75 BMs) or non–small cell lung cancer (n = 11 with 32 BMs) treated with ICI or TT who had 18F-FET PET (n = 60 scans) for treatment monitoring from 2015 to 2019. Most patients (n = 37; 92.5%) had radiotherapy during the course of the disease. In 27 patients, 18F-FET PET was used to differentiate treatment-related changes from BM relapse after ICI or TT. In 13 patients, 18F-FET PET was performed for response assessment to ICI or TT using baseline and follow-up scans (median time between scans, 4.2 mo). In all lesions, static and dynamic 18F-FET PET parameters were obtained (i.e., mean tumor-to-brain ratios [TBR], time-to-peak values). Diagnostic accuracies of PET parameters were evaluated by receiver-operating-characteristic analyses using the clinical follow-up or neuropathologic findings as a reference. Results: A TBR threshold of 1.95 differentiated BM relapse from treatment-related changes with an accuracy of 85% (P = 0.003). Metabolic responders to ICI or TT on 18F-FET PET had a significantly longer stable follow-up (threshold of TBR reduction relative to baseline, ≥10%; accuracy, 82%; P = 0.004). Furthermore, at follow-up, time to peak in metabolic responders increased significantly (P = 0.019). Conclusion: 18F-FET PET may add valuable information for treatment monitoring in BM patients treated with ICI or TT.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ 32887757
%U <Go to ISI:>//WOS:000658416500008
%R 10.2967/jnumed.120.248278
%U https://juser.fz-juelich.de/record/890281